BTIG analysts remain high on Boston Scientific (NYSE:BSX) following meetings with the company's management this week.

Atrial fibrillation (AF or AFib) is one of the most common abnormal heart rhythms, affecting nearly 38 million people worldwide — a figure projected to nearly triple by 2030. Boston Scientific BSX ...

Boston Scientific, Inc. BSX recently gained the FDA’s approval for the FARAPULSE Pulsed Field Ablation (“PFA”) system, which is indicated for the isolation of pulmonary veins in the treatment of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Boston Scientific has received US Food and Drug Administration (FDA) approval for the Farapulse Pulsed Field Ablation (PFA) system for the isolation of pulmonary veins in the treatment of ...

Boston Scientific Corp BSX will present results from ADVENT pivotal trial for its Farapulse Pulsed Field Ablation (PFA) system at the 2023 European Society of Cardiology Congress on 27 August. ADVENT ...

Pulsed-Field Ablation, one of the hottest and most competitive segments in medtech, was a major topic of discussion during Boston Scientific’s presentation at the J.P. Morgan Healthcare Conference ...

Boston Scientific, Abbott and Medtronic all presented successful readouts of their cardiac devices during the Heart Rhythm Society’s (HRS) 2026 annual meeting. Medtronic presented new, late-breaking ...